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Abbreviations and acronyms: ADCC, antibody-dependent cellular cytotoxicity; CNS, central nervous system; DLBCL, diffuse large
B-cell lymphoma; FcgRIIIA/CD16, type III low-affinity Fcg receptor; GrzB, Granzyme B; IFNg, interferon g; NK,
natural killer cells; PBMC, peripheral blood mononuclear cell; PMLBCL, primary mediastinal large B-cell lymphoma; R-CHOP,
rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in
rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism. We
evaluated the phenotypic and functional assets of peripheral blood NK cell subsets in 32 newly-diagnosed diffuse large
B-cell lymphoma (DLBCL) patients and in 27 healthy controls. We further monitored long-term modifications of patient
NK cells for up to 12 months after rituximab-based immunochemotherapy. At diagnosis, patients showed a higher
percentage of CD56dim and CD16C NK cells, and a higher frequency of GrzBC cells in CD56dim, CD56bright, and CD16C
NK cell subsets than healthy controls. Conversely, DLBCL NK cell killing and interferon g (IFNg) production capability
were comparable to those derived from healthy subjects. Notably, NK cells from refractory/relapsed patients exhibited a
lower “natural” cytotoxicity. A marked and prolonged therapy-induced reduction of both “natural” and CD16-
dependent NK cytotoxic activities was accompanied by the down-modulation of CD16 and NKG2D activating receptors,
particularly in the CD56dim subset. However, reduced NK cell killing was not associated with defective lytic granule
content or IFNg production capability. This study firstly describes tumor-associated and therapy-induced alterations of
the systemic NK cell compartment in DLBCL patients. As these alterations may negatively impact rituximab-based
therapy efficacy, our work may provide useful information for improving immunochemotherapeutic strategies.
Introduction
Natural killer (NK) cells are an essential component of innate
immunity and surveillance against malignancies. Their anti-leu-
kemic potential and ability to regulate normal and neoplastic
haematopoietic precursors has recently raised considerable inter-
est. Their effector functions also represent a crucial factor in
determining the response to anticancer therapy.1-3 Diffuse large
B-cell lymphoma (DLBCL) is the most common aggressive
B-cell lymphoma, with heterogeneous genetic, phenotypic, and
clinical features.4-6 The immunochemotherapeutic association
of anti-CD20 monoclonal antibody (mAb) rituximab, with
cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) has significantly improved the survival of DLBCL
patients, and represents the current standard-of-care with an effec-
tive outcome in 60–80% of cases.6,7 NK cell-mediated, CD16-
dependent antibody-dependent cytotoxicity (ADCC) likely plays
a major role in determining the efficacy of rituximab-based
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therapy.8-10 Indeed, structural and/or functional characteristics of
CD16 receptor that affect anti-CD20 mAb-mediated ADCC in
vitro,11-13 also impact on NK cell activation status14 and patient
outcome in vivo.10,15-18
NK cells are resident in peripheral blood and in some lym-
phoid and non-lymphoid organs, and are promptly recruited to
tumor sites.19 The 2 main NK cell subsets in the periphery are
thought to represent sequentially ordered differentiation steps.
CD56dim NK cells with high cytotoxic potential account for the
vast majority of peripheral blood NK cells, are primarily CD16C
(FcgRIIIA low-affinity Fc receptorC), and most likely represent
the final maturation step. CD56bright NK cells also home to sec-
ondary lymphoid organs, bear low or absent CD16, display
higher capability to produce cytokines and lower cytotoxic activ-
ity, and are thought to represent the immediately preceding dif-
ferentiation stage.20-22
Antitumor NK cell activation and effector functions are finely
regulated by the balance between opposing signaling pathways
initiated by activating and inhibitory, MHC Class I-specific,
receptors.23-26 While CD16 is responsible for ADCC against
IgG-coated cells,27,28 several activating receptors cooperatively
trigger natural cytotoxicity against tumor cells.23-26 Among these,
killer cell lectin-like receptor K1 (KLRK1, better known as
NKG2D) plays an important role in the immunosurveillance
against human and mouse model lymphoma, by recognizing
stress-induced ligands belonging to the MIC (MICA and MICB)
and ULBP (ULBP1–6) families.29-35 Expression and/or func-
tional capability of activating receptors is orderly acquired during
NK cell differentiation20-22 and can be modulated upon activa-
tion and/or ligand engagement.29-37 Activated NK cells also rap-
idly secrete a variety of cytokines and chemokines, such as
interferon g (IFNg), that amplify the recruitment and activation
of other participants to the antitumor response.19,38
Although peripheral blood lymphopenia at diagnosis and dur-
ing treatment has been widely reported as a negative prognostic
factor in DLBCL,39-41 this phenomenon, a reflection of host sys-
temic immunity, remains poorly characterized. Few studies have
addressed the characterization of the NK cell compartment in
DLBCL patients. A notable study suggested the relevance of a
low NK cell count as an important prognostic factor in the pre-
rituximab era,42 while a recent report described the concomitant
defect of CD16 expression and ADCC in NK cells of a small
group of DLBCL patients at diagnosis.43 While it has been
shown that rituximab infusion rapidly (within hours) induces
changes in the NK cell phenotype, activation status, and ADCC
activity,14,44 information on the long-term effects of rituximab-
based therapy on NK cells are still mostly lacking.
In this prospective study, we have longitudinally assessed the
phenotypic and functional long-term dynamics of the peripheral
blood NK cell compartment, in a cohort of newly diagnosed
DLBCL patients undergoing rituximab-based immunochemo-
therapy. As the phenotypic and functional profile of the host’s
NK cells might significantly contribute to the success of immu-
nochemotherapy strategies, the novel information provided by
this study may prove useful for the development of focused and
innovative therapeutic approaches.
Results
Phenotypic and functional assets of the peripheral NK cell
compartment in DLBCL patients at diagnosis
We initially assessed the profile of the peripheral blood (PB)
NK cell compartment in a cohort of newly diagnosed DLBCL
patients and age- and sex-matched healthy controls. Although
patients showed significantly lower total lymphocytes counts
(Fig. 1A), the absolute numbers of total CD3-CD56C NK cells
and of CD56dim, CD56bright, and CD16C subsets were compara-
ble between patients and healthy subjects (Fig. 1B). However,
the relative frequency of total CD3–CD56C NK cells, and of
CD56dim and CD16C, but not of CD56bright, NK cell sub-
sets, were significantly higher in patients than in controls
(Fig. 1C).
NK cells are endowed with cytotoxic activity and with the
capability to promptly produce cytokines and chemokines.19,38 A
considerably higher frequency of cells expressing the cytotoxic
granule marker Granzyme B (GrzB) characterized CD56dim,
CD56bright and CD16C NK cell populations in patients’ PBMC
(Fig. 1D); nevertherless, either “natural” (anti-K562 erythroleu-
kemia cell line) and CD16-dependent (anti-P815Canti-CD16
mAb) cytotoxic activities were comparable between patient and
control-derived NK cells (Fig. 1E). NK cell capability to produce
IFNg, as evaluated by the frequency of cytokine-producing cells
upon short-term stimulation with phorbol 12-myristate 13-ace-
tate (PMA) and ionomycin, was also comparable between
patients and controls (Fig. 1F).
Taken altogether, these data indicate that the peripheral blood
NK cell compartment of newly diagnosed DLBCL patients (time
point 1 [T1]), although being quantitatively and functionally
normal, shows a higher representativity over lymphocytes, and
displays a higher cytotoxic potential.
Long-term dynamics of peripheral blood NK cell subsets
in DLBCL patients undergoing rituximab-based
immunochemotherapy
The absolute counts of CD3¡CD56C NK cells, as well as
their CD56dim and CD56bright subsets, were transiently
decreased at mid-therapy time point (T2), and had recovered
by the end of therapy (T3, within one month after the last
treatment course); the diminution was significant, as com-
pared to either healthy controls (Figs. 2A-C) or pre-therapy
samples (T1, Table S1A-Clink>). Interestingly, the absolute
count of CD16-expressing CD3-CD56C NK cells showed a
marked and prolonged reduction, as it persisted till the end
of therapy time point (T3), and had recovered by 3 months
later (T4) (Fig. 2D; Table S1D).
The percentage of total, CD56dim, and CD16-expressing NK
cells (over lymphocytes), that were higher at diagnosis (T1),
became comparable to controls from T2 till the end of the fol-
lowing observation period (12 months) (Figs. 2E-F, and H).
CD56bright NK cells were slightly elevated only at 12 months
after therapy (T6, Fig. 2G).
Altogether, these results show that while circulating CD56dim
and CD56bright NK cell counts transiently decrease during
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therapy, the diminution of CD16-
expressing NK cells is more
prolonged.
Long-term dynamics of CD16
receptor expression on PB NK
cells of DLBCL patients
Our findings suggest the occur-
rence of therapy-induced downre-
gulation of CD16 receptor on NK
cells in DLBCL patients. We next
analyzed in depth the dynamics of
CD16 expression on circulating
NK cell subsets. Interestingly, the
fraction of NK cells expressing
CD16 receptor was markedly and
significantly reduced at T3
(within one month upon therapy
completion), with respect to
healthy controls (Fig. 3A) or to
pre-therapy levels (Table S2A-C).
A significant diminution of
CD16C cells selectively occurred
on CD56dim, and not on
CD56bright NK cells (Figs. 3B-C,
respectively); however, CD16
receptor intensity (expressed as
specific mean fluorescence inten-
sity, MFI) was markedly reduced
on CD56bright NK cells, at T3
(Figs. 3D-E, respectively).
Taken altogether, these data
suggest that immunochemother-
apy induces the diminution of cir-
culating CD16C NK cells. This
decrease: a) persists over one
month after therapy completion;
b) more deeply affects the
CD56dim subset; and and c) is the
combined result of diminished
NK cell absolute counts, observed
during therapy, and CD16 down-
regulation on NK cells, recorded
after the completion of therapy.
Transient down-modulation
of NKG2D activating receptor
on NK cells in DLBCL patients
undergoing
immunochemotherapy
NKG2D is an important acti-
vating receptor for “natural” cytotoxicity29-35 and also partici-
pates in CD16-dependent killing.45,46 The frequency of
NKG2DC NK cells at diagnosis (T1) was comparable between
DLBCL and healthy controls. However, it transiently decreased
during therapy (T2), with the diminution more persistently
observed in the CD16C fraction (sustained until 3 months after
the end of therapy, T4, Figs. 4A-B). NKG2D downregulation
selectively occurred on CD56dim NK cells (Fig. 4Ci), notably,
affecting only the CD16C fraction (Fig. 4Cii-iii). Conversely,
NKG2D expression on either CD16C or CD16- CD56bright NK
Figure 1. Phenotypic and functional assessment of the peripheral NK cell compartment in DLBCL patients at
diagnosis. Peripheral blood mononuclear cells PBMCs of newly diagnosed diffuse large B cell lymphoma
(DLBCL) patients (gray boxes) and healthy age- and sex-matched controls (empty boxes) were analyzed for:
(A) total lymphocyte counts, (B) natural killer (NK) cell subset absolute counts, and (C) NK cell subsets as a
percentage of lymphocytes. (D) The percentage of Granzyme B-positive (GrzBC) cells was calculated within
each NK cell subset. (E) “Natural” (anti-K562) and CD16-dependent (anti-P815 C anti-CD16 monoclonal anti-
body [mAb]) cytotoxic activities are expressed in lytic units at 10% cytotoxicity/106 PBMC. (F) The percentage
of interferon g (IFNg)-producing cells was calculated on gated CD3-CD56C NK cells. Bars represent median
gated CD3-CD56C NK cells. Bars represent median and 10–90 percentile; dots represent outliers. *P <0.05,
**P  0.01, ***P< 0.0005, ****P D 0.000001.
www.tandfonline.com e990773-3OncoImmunology
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cells did not vary significantly
over the entire follow-up period
(Fig. 4Di-iii).
Soluble NKG2D ligands
can induce NKG2D receptor
downregulation in cancer
patients.29-33 However, plasma
levels of the NKG2D ligands
MICA, MICB, ULBP1 and
ULBP2 did not differ signifi-
cantly between pre-therapy
(T1) DLBCL patients and
healthy controls. MICB dimi-
nution was the only variation
observed during therapy (T2)
( Fig. S1).
These results show that
immunochemotherapy is associ-
ated with the down-modulation
of NKG2D activating receptor
on CD16C CD56dim NK cells,
and suggest that circulating
NKG2D ligands are not
involved in this phenomenon.
Long-term dynamics of
“natural” and CD16-
dependent cytotoxic activities
of DLBCL PBMCs
The aforementioned data
show that immunochemother-
apy is associated with a pro-
longed downregulation of
CD16 and NKG2D activating
receptors on NK cells, particu-
larly the highly lytic CD56dim
subset.20-22 Interestingly, both
“natural” and CD16-dependent
cytotoxic activities were
strongly reduced during and up
to one month after the end
of therapy (T2 and T3, respec-
tively), relative to either pre-
therapy levels (Table S3A and
B) or healthy controls (Fig. 5).
NK cytotoxic activities returned
to levels comparable to those of
control NK cells by 3 months
after therapy completion (T4).
Taken together, our results
show that immunochemother-
apy-induced downregulation of
CD16 and NKG2D activating
receptors is temporally related to
the impairment of both "natural"
Figure 2. CD56dim and CD16C NK cell absolute counts transiently decrease in DLBCL patients during immuno-
chemotherapy. Peripheral blood mononuclear cells (PBMCs) of diffuse large B cell lymphoma (DLBCL) patients
at different time points (T1-T6, gray boxes) and of healthy controls (HC, empty boxes) were analyzed for: (A-D)
the absolute counts of total CD3-CD56C natural killer (NK) cells and their subsets, obtained by combining com-
plete blood counts and immunocytofluorimetric analysis; (E-H) the percentage of total CD3-CD56C NK cells
and their subsets within lymphocytes. Bars represent median and 10–90 percentile; dots represent outliers. *P
< 0.05, **P  0.01, ***P  0.001, ****P < 0.0005 vs. controls.
e990773-4 Volume 4 Issue 3OncoImmunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 St
ud
i la
 Sa
pie
nz
a] 
at 
03
:16
 05
 Ja
nu
ary
 20
16
 
and CD16-dependent in vitro
cytotoxic capability. In accor-
dance, CD16-dependent cyto-
toxic activity of NK cells derived
from individual patients at T3
significantly correlated with
NKG2D expression on CD16C,
but not on CD16- CD56dim NK
cells (Fig. S2A-C).
Long-term dynamics of NK
functional competence in
DLBCL patients
The frequency of GrzBC NK
cells in patients remained signifi-
cantly higher than in healthy con-
trols till T4 and T5 (3 and 6
months after the end of therapy,
respectively), in CD56dim and
CD56bright NK cell subsets
(Fig. 6A and B). At variance, the
percentage of IFNg-producing
NK cells was transiently elevated
at T3, although comparable to
NK cells derived from healthy
controls at all the remaining time
points (Fig. 6C).
These results indicate that the
expanded pool of cytotoxic gran-
ule-containing cells that charac-
terized the DLBCL NK
compartment at diagnosis recal-
citrantly returned to normal lev-
els, albeit well after the end of
the treatment.
Refractory/early-relapsed
patients show defective
“natural” cytotoxicity at
diagnosis
The analysis of PBMC cyto-
toxic activity, after patients
stratification, shows that
patients that were resistant to
therapy, or that underwent
early relapse (within one year
after diagnosis), displayed a sig-
nificantly lower “natural," but
not CD16-dependent, cytotoxic
activity at diagnosis, as compared either with controls, or
with patients attaining remission lasting more than 2 y
(Fig. 7A and B). NK cell subset absolute counts and percen-
tages were comparable between the 2 groups of patients
(Fig. 7C). Clinical parameters of remitting and resistant
patients are reported in Table S4. This observation, although
based on a limited number of subjects, suggests that defective
NK cell functional activity at diagnosis may be associated
with immunochemotherapy failure.
Discussion
NK cells represent an important component of tumor immu-
nosurveillance, and their effector functions may contribute
Figure 3. Long-term dynamics of CD16 expression on NK cell subsets in DLBCL patients upon immunochemo-
therapy. Peripheral blood mononuclear cells (PBMCs) of diffuse large B cell lymphoma (DLBCL) patients at dif-
ferent time points (T1-T6, gray boxes) and of healthy controls (HC, empty boxes) were analyzed for: (A) the
percentage of CD16C cells over CD3-CD56C natural killer (NK) cells; (B-C) the percentage of CD16C cells and
(D-E) the specific mean fluorescence index (MFI) of CD16 receptor calculated within CD56dim (B, D) and
CD56bright (C, E) NK cell subsets. Bars represent median and 10–90 percentile; dots represent outliers.
*P < 0.05, ****P < 0.0005 vs. controls.
www.tandfonline.com e990773-5OncoImmunology
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significantly to the success of rituximab-based anti-lymphoma
therapies.8-10,15-18 Characterization of NK cell phenotypic and
functional assets in newly diagnosed DLBCL patients has been
scarce. Here, we first to report
baseline and long-term analysis
of the phenotypic and functional
dynamics of peripheral blood
NK cell subsets in DLBCL
patients. Our data reveal tumor-
associated as well as therapy-
dependent alterations of the sys-
temic NK cell compartment.
At diagnosis, the major NK
cell subsets (CD56dim,
CD56bright, CD16C), although
in the normal range of peripheral
blood absolute counts, had a
higher frequency compared to
age- and sex-matched healthy
individuals. This can be
explained by the decreased abso-
lute counts of B and CD4C T
lymphocytes (MC Cox, G Pal-
mieri et al., manuscript in prepa-
ration), which underlies the low
absolute lymphocyte count
observed in DLBCL patients.
“Natural” and CD16-dependent
cytotoxic activities were compa-
rable between DLBCL and con-
trols; however, refractory/early-
relapsed patients showed a lower
“natural” cytotoxic activity at
diagnosis, as compared to either
patients achieving durable remis-
sion or to healthy subjects.
Information on NK cell phenotypic and functional assets in
newly diagnosed DLBCL patients has, so far, been scarce. In
accordance with our data, an elevated NK cell frequency has
Figure 4. Long-term dynamics of
NKG2D activating receptor on NK
cell subsets in DLBCL patients upon
immunochemotherapy. Peripheral
blood mononuclear cells (PBMCs)
of diffuse large B cell lymphoma
(DLBCL) patients at different time
points (T1-T6, gray boxes) and of
healthy controls (HC, empty boxes)
were analyzed for the percentage
of NKG2DC cells in: total
CD3¡CD56C NK cells (A), CD16C NK
cells (B), or within CD56dim (C) and
CD56bright (D) NK cell subsets; the
frequency of NKG2DC cells was
evaluated in each subset, as a
whole (i), and in the CD16C (ii) and
CD16- (iii) fractions. Bars represent
median and 10–90 percentile; dots
represent outliers. *P < 0.05, **P <
0.01, ***P  0.001 vs. controls.
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been previously reported in
patients.47 Furthermore, higher
absolute NK cell counts and
“natural” cytotoxicity at diagnosis
have both shown to positively cor-
relate with response to therapy,
either in the pre-rituximab
era,42,48-49 and more recently in
immunochemotherapy-treated
patients.50 Our results, although
obtained in a limited number of
patients, confirm that defective
basal “natural” killing activity asso-
ciates with treatment failure, thus
stressing the role of NK cell cyto-
toxic capability in the success of
rituximab-based therapy. A recent
report described defective NK cell
degranulation as a proxy for "natu-
ral" and ADCC activities in a
group of newly diagnosed DLBCL
patients.43 As these authors did not provide information on
demographic and clinical parameters of patients and controls,
and on therapy outcome, the discrepancy with our results may
depend on unknown patient characteristics and/or differences in
the experimental assays employed (NK cell degranulation vs. kill-
ing and ADCC vs. CD16-dependent cytotoxicity).
The frequency of cytotoxic granule-containing cells was
markedly elevated in all major NK cell populations of DLBCL
patients, whereas the percentage of IFNg-producing cells was
comparable to that of in healthy subjects. GrzB-containing cyto-
toxic granules are acquired during NK cell differentiation, and
their biosynthesis is modulated by proinflammatory cytokines or
members of the gc chain cytokine family.
20-22 The higher fre-
quency of GrzBC NK cells, particularly in the CD56bright subset,
may thus underlie a state of chronic activation and/or a perturbed
differentiation process, which may stem from a tumor-dependent
altered microenvironment.
Rituximab-based immunochemotherapy induced a complex
phenotypic and functional perturbation of peripheral blood NK
compartment. A profound and protracted impairment of both
“natural” and CD16-dependent in vitro cytotoxic activities was
observed during therapy, it persisted well over one month after
the end of treatment, and had recovered 3 months later; this was
paralleled by a significant reduction of CD16 and NKG2D acti-
vating receptors, that more markedly affected the CD56dim NK
cell subset. Interestingly, neither the lytic potential nor the capa-
bility to produce IFNg were defective in DLBCL patients during
the same time period. Moreover, the percentage of CD56dim and
CD56bright subsets relative to total lymphocytes remained com-
parable to healthy subjects. However, NK absolute counts tran-
siently diminished during therapy cycles, and returned to normal
levels by one month after the end of therapy; this may be
accounted by immunochemotherapy-induced NK cell margin-
ation and/or re-localization, or alternatively, drug-induced
toxicity.
Taken together, these results suggest that the defective in vitro
cytotoxic activity neither depends on a gross functional
impairment, nor on the exhaustion of the lytic potential, nor on
a reduced frequency of peripheral blood NK cells. Moreover, the
short in vivo half-life of the chemotherapeutic drugs that were
administered, together with the fast and reversible kinetics with
which they partially affect in vitro and in vivo NK cell killing
ability,51-53 make it unlikely that the impaired NK cytotoxicity
of DLBCL patients is attributable to the direct effect of cytotoxic
drugs, especially for the end of treatment time point. In contrast,
rituximab persists at detectable levels long after the end of ther-
apy cycles.10,53,54
The downregulation of CD16 and NKG2D activating NK
cell receptors on the more lytic CD56dim subset19-22 suggests that
defective recognition and/or activation mechanisms may rather
play a role in the impairment of "natural" and CD16-dependent
cytotoxic activities. The mechanisms underlying receptor down-
modulation are presently unknown, although it has been widely
reported that cell activation and/or ligand engagement can
induce the modulation of NK activating receptors through sev-
eral mechanisms.29-37
CD16 down-modulation, the upregulation of activation
markers, and enhanced ADCC capability occur in a matter of
hours after rituximab infusion, with some of these effects depend-
ing on the presence of CD16 high affinity polymorphism;14,44
however, the long-term effects of rituximab-based immunoche-
motherapy on CD16 expression levels have not been previously
studied in DLBCL patients.
Immunosuppressive cytokines, as well as chronic contact with
cell-associated or soluble ligands, may induce NKG2D receptor
downregulation, as shown in vitro and in tumor patients in
vivo.29-34 However, plasma levels of several NKG2D ligands
were not increased in DLBCL patients. Moreover, NKG2D
dowregulation selectively affected the CD16C CD56dim NK sub-
set. This finding argues against a role for soluble, systemic
Figure 5. Long-term dynamics of “natural” and CD16-dependent cytotoxic activities in peripheral blood of
DLBCL patients. (A) “natural” (anti-K562) and (B) CD16-dependent (anti-P815 C anti-CD16 monoclonal
antibody [mAb]) cytotoxic activities of peripheral blood mononuclear cells (PBMCs) of diffuse large B cell
lymphoma (DLBCL) patients at different time points (T1-T6, gray boxes) and of healthy controls (HC, empty
boxes); data are expressed in lytic units at 10% cytotoxicity/106 PBMC. Bars represent median and 10–90 per-
centile; dots represent outliers. ***P < 0.0001, ****P < 0.00005 vs. controls.
www.tandfonline.com e990773-7OncoImmunology
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mediators in NKG2D dowregulation. Our results suggest that a
more effective, CD16-dependent, interaction with rituximab-
coated, NKG2D ligand-expressing lymphoma cells may contrib-
ute to down-modulation of the NKG2D receptor. Indeed,
DLBCL cells can constitutively express NKG2D ligands, that
may be further enhanced by chemotherapy-triggered DNA dam-
age response.29-34,56,57
Overall, our results suggest that the therapy-driven, CD16-
dependent, continuous stimulation leads to a prolonged NK
cell phenotypic modulation and in vitro functional
impairment. These alterations may be highly significant also
for in vivo NK cell cytotoxic activity against DLBCL cells,
and as such, may impact rituximab-based therapy efficacy.
Although CD16 engagement by IgG-coated target cells is the
sole trigger for ADCC,26,27 its activity can be enhanced by
NKG2D engagement;45,46 moreover, it has been shown that
NKG2DC NK cells preferentially perform ADCC.44 Indeed,
the interplay between CD16 and NKG2D activating
receptors is undergoing active
investigation for therapeutic
purposes.58
Our study also revealed that
the expanded pool of cytotoxic
granule-containing NK cells in
DLBCL patients at disease onset
does normalize, albeit only after a
prolonged interval following the
completion of therapy. This
delayed kinetics may reflect a slow
NK cell turnover, possibly due to
lymphopenia- and/or age-associ-
ated expansion of long-lived
memory NK cells.20-22,59 Addi-
tionally, a long-lasting perturba-
tion in the NK differentiation/
maturation process, either in
the bone marrow and/or in the
periphery, may also be involved
in this process. This perturba-
tion would be initially depen-
dent on the presence of the
tumor and afterward be sus-
tained by chemotherapy-trig-
gered alterations of the bone
marrow microenvironment.60,61
In sum, our pioneering and
comprehensive analysis has shown
that the peripheral NK cell com-
partment in DLBCL patients is
affected by both tumor-associated
alterations that normalize late
after the achievement of clinical
remission as well as immunoche-
motherapy-dependent quantita-
tive, phenotypic and functional
alterations that recover with dis-
tinct kinetics. Immunochemotherapy-induced alterations of NK
cell functionality might partly explain why a dose-dense rituxi-
mab regime may not lead to improved outcome.62,63
Innovative combination strategies aiming to potentiate NK
cell effector functions and newly devised anti-CD20 antibodies
to target malignant B cells are promising new tools in lymphoma
therapy.64-68 The novel information provided by our study may
be relevant for the improvement of anticancer immunotherapy,
as well as in other settings in which therapeutic efficacy relies on
NK-dependent effector functions.
Materials and Methods
DLBCL patients and controls
All patients included in the prospective study were referred to
the Hematology Unit of Sant’Andrea Hospital in Rome. Newly-
diagnosed DLBCL patients with Stage II-IV or I bulky were
Figure 6. Long-term dynamics of NK cell functional competence in DLBCL patients. Peripheral blood mono-
nuclear cells (PBMCs) of diffuse large B cell lymphoma (DLBCL) patients at different time points (T1-T6, gray
boxes) and of healthy controls (HC, empty boxes) were analyzed for: the percentage of GrzBC cells in (A)
CD56dim and (B) CD56bright natural killer (NK) cell subsets. (C) The percentage of interferon g (IFNg)-producing
cells was determined by intracellular staining and cytofluorimetric analysis, and calculated on gated
CD3¡CD56C NK cells. Bars represent the median and 10–90 percentile; dots represent outliers. *P < 0.05, **P
< 0.01, ***P < 0.00005, ****P < 0.000005 vs. controls.
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included in the study; exclusion
criteria included positivity for
human immunodeficiency virus
(HIV) or hepatitis (HBV/
HCV), presence of opportunistic
infections, central nervous sys-
tem (CNS) involvement, leuke-
mic dissemination, or previous
chemotherapy-treated neoplasia.
Demographic and clinical char-
acteristics of patients and healthy
controls are in Table 1. Patients
with conventional DLBCL were
treated with 6 cycles of R-CHOP-
21 or R-CHOP-14 (high risk
<60 years); primary mediastinal
large B-cell lymphoma
(PMLBCL) patients were treated
with 12 cycles of RMACOPB69
and consolidation radiotherapy. In
R-CHOP-treated, rituximab was
administered at days 0 and C7 of
cycle 1, and with chemotherapy
cycles thereafter. The 8th and last
rituximab infusion was adminis-
tered 25-30 d after the last course
of immunochemotherapy.
Patients were analyzed at diag-
nosis (T1), at mid-therapy
(between 2nd and 3rd cycle of R-
CHOP, and between 6th and 7th
week of RMACOPB, T2),
within one month after immuno-
chemotherapy completion and
immediately before last rituxi-
mab infusion (T3), at 3 (T4), 6
(T5), and 12 (T6) months after
the end of immunochemother-
apy. Patients that were consid-
ered to be non-responders after
mid-treatment restaging,70 or
that relapsed during the study
period, were not analyzed
further.
The study was approved by
our Institutional Review Board
and was conducted in accor-
dance with the regulations of
health information protection
policies, and with the Declara-
tion of Helsinki. All patients and
controls gave informed consent to the study.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized blood samples by Lymphoprep (Cedarlane,
Ontario, Canada) density gradient centrifugation. PBMCs were
immediately used for cytotoxicity assay, and stored at ¡80C in
10% dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, USA)
and 90% fetal calf serum (FCS; Euroclone, Milan, Italy), for phe-
notypic and functional analyses. Cells were rapidly thawed at
Figure 7. Defective “natural” cytotoxicity at diagnosis in refractory/early-relapse patients. (A) “natural” (anti-
K562) and (B) CD16-dependent (anti-P815 C anti-CD16 mAb) cytotoxic activities of peripheral blood mononu-
clear cells (PBMCs) in diffuse large B cell lymphoma (DLBCL) patients that attained long-lasting remission
(Rem, gray symbols, n D 25 ), or that were refractory/early-relapsed (Refr/Rel, black symbols, n D 6 ), and of
healthy controls (HC, empty boxes, n D 27); data are expressed in lytic units at 10% cytotoxicity/106 PBMC.
Bars represent median and 10–90 percentile. *P < 0.05. (C) Natural killer (NK) cell subset absolute counts and
percentages in remitting and refractory/relapsed patients; amedian value; b(25–75 percentile range); cP value;
ns, not significant.
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37C, washed, and rested overnight in RPMI 1640 medium sup-
plemented with 10% FCS and 1% glutamine (all from Euroclone;
completemedium), at 37C in 5%CO2 atmosphere, prior to stim-
ulation, immunostaining and cytofluorimetric analysis.
Evaluation of intracellular IFNg
PBMCs were stimulated with 50 ng/mL phorbol 12-myristate
13-acetate (PMA) and 0.5mg/mL ionomycin at 37 C for 6h in
complete medium, in the presence of the intracellular trafficking
inhibitors Monensin (50 mM, added at the beginning of stimula-
tion) and Brefeldin A (10mg/mL, added after 1h) (all from
Sigma-Aldrich Srl, Milan, Italy). Cell samples were then fixed,
permeabilized, and stained with phycoerythin (PE)-conjugated
anti-IFNg antibody or isotype control mAb (both from BD Bio-
sciences, Milan, Italy).
Immunostaining procedures and cytofluorimetric analysis
NK cell subsets were identified by a combination of physical
parameters and surface staining with optimal dilutions of fluoro-
chrome-conjugated mAbs (anti-CD3 Alexafluor488, anti-CD16
PE-Cy7, anti-CD56 APC, all from BD Biosciences), for 30 min
at 4C. The values of complete blood counts and cytofluorimet-
ric analysis percentages were used to calculate the absolute num-
ber of lymphocyte subsets.
For intracellular staining, cell samples were stained for surface
antigens, washed with phosphate-buffered saline, fixed with 2%
paraformaldehyde (Sigma-Aldrich) for 20 min, permeabilized
with 0.5% saponin (Sigma-Aldrich) in 1% FCS for 30 min, and
stained with PE-conjugated anti-IFNg or anti-Granzyme B
(Enzo Life Science, Inc., USA) antibodies, or isotype control
mAb, in the presence of 0.5% saponin/1% FCS.
All samples were analyzed with a FACScalibur (BD Bioscien-
ces) flow cytometer, using CellQuest Pro (BD Biosciences) and
FlowJo v9.3.2 (Treestar, Ashland, OR) data analysis software.
Lymphocytes were defined by gating on forward and side scatter
physical parameters. The threshold for antigen positivity was set
on the basis of a matched isotype control mAb-stained sample,
whose positivity never exceeded 0.5% of gated events.
Cytotoxicity assay
“Natural” (anti-K562 erythroleukemia cell line) and CD16-
dependent (anti-P815 murine mastocytoma cell line C anti-
CD16 mAb) cytotoxic activities were measured with a 4 h 51Cr-
release assay, as previously described.71 Briefly, K562 and P815
target cells were labeled with 51Cr (PerkinElmer, MA, USA)
(100 mCi/1 £ 106 cells) for 75 min at 37C. Serial dilutions of
PBMC, as effector cells, were plated in U-bottom 96-well plates
in complete medium supplemented with 10 mM Hepes (Sigma-
Aldrich), together with 51Cr-labeled target cells (5 £ 103 cells/
well), in the absence (K562) or in the presence (P815) of optimal
concentration of anti-CD16 mAb (B73.1 clone, kindly provided
by Dr G. Trinchieri, Cancer and Inflammation Program, NCI,
Frederick, USA). After 4 h incubation at 37C, released radioac-
tivity in 100 mL of supernatant was counted with a Cobra
Gamma Counter (Packard-PerkinElmer). Percent specific lysis
was calculated according to the formula: % specific lysis D
(experimental release cpm - spontaneous release cpm)/(maximum
release cpm - spontaneous release cpm) £ 100. Spontaneous
release never exceeded 5% of total release. Basal cytotoxicity
against P815 cell line (in the presence of anti-CD56 mAb, as iso-
type control) never exceeded spontaneous release (data not
shown).
Cytotoxicity is expressed in lytic units at 10% cytotoxicity/
million PBMC (LU10/10
6), calculated using D. Coggin’s soft-
ware. One lytic unit is defined as the number of effector cells nec-
essary to lyse 10% of target cells.
Evaluation of soluble NKG2D ligands
Enzyme-linked immunosorbent assays (ELISA) to detect
soluble MICA, MICB and ULBP1 were obtained from R&D
Systems (Minneapolis, MN, USA), and performed using
2 mg/mL anti-MICA capture mAb (AMO1; BAMOMAB,
Germany) essentially as previously described72. Soluble
ULBP2 was detected as previously described.73 Absorbance
values of triplicate samples were obtained by subtracting read-
ings at 540 nm from readings at 450 nm. Net absorbance
was obtained by subtracting the reagent blank absorbance.
Before the assay, plasma samples were diluted in PBS con-
taining 0.1% Triton X-100 (vol/vol), and incubated for
30 min at 37C.
Statistical analysis
Healthy controls and patients were compared with the 2-
tailed Mann-Whitney U test. Patients at different time points
Table 1. Demographic and clinical characteristics of DLBCL patients and
controls
patients controls P
median age, y (range) 59 (37–79) 57 (29-73) nsc
gender, M/F 20a (62)b/12 (38) 12 (37)/15 (63) ns
Ann Arbor stage
I-II 10 (31)
III-IV 22 (69)
Histology
DLBCL 28 (88)
PMLBCL 4 (12)
PS
0-1 20 (62)
2-4 12 (38)
IPI
0-2 18 (56)
3-5 14 (44)
BM involvement
yes 12 (37)
no 20 (63)
Extra-nodal sites
< D 1 21 (66)
>1 11 (34)
Complete remission with first
line treatment
28 (87)
Abbreviations: BM, bone marrow; DLBCL, diffuse large B cell lymphoma; IPI,
International Prognostic Index scores (0–2 and 3–5); PMLBCL, primary medi-
astinal large B cell lymphoma; PS, performance status of Eastern Coopera-
tive Oncology Group (ECOG).
anumber; bpercentage; cnot significant.
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were compared with the Wilcoxon signed rank test. Pearson cor-
relation test was employed for correlation analysis. Statistical
analysis was performed with PRISM v.6 (GraphPad Software,
San Diego, CA, USA) and SPSS v.20 (IBM Italia SpA, Segrate,
MI, Italy) softwares. P values <0.05 (2-sided) were considered
significant.
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